• Recruiting

NCT03683277: Phase 2: Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

Updated: May 28

IFM2014-01


ifm 2014

NCT03683277: Phase 2: Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)


IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)


This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.


Sponsor:

Intergroupe Francophone du Myelome


Collaborators:

AXONAL

Nantes University Hospital

University Hospital, Grenoble

Euraxi Pharma


Location

France

 

ClinicalTrials.gov Identifier: NCT03683277


Official Title: Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

First Posted : September 25, 2018


Click here to see details on ClinicalTrials.gov


https://www.myelome.fr/

 

Drug: Ixazomib/Pomalidomide/Dexamethasone

 


Posts Archive